Dublin, Feb. 19, 2026 (GLOBE NEWSWIRE) -- The "Pipeline of Claudin 18.2-Targeted Immunotherapy" report has been added to ResearchAndMarkets.com's offering. This competitive intelligence report about ...

TORL-1-23 Demonstrates Clinically Meaningful, Durable and Confirmed Responses with a Generally Manageable Safety Profile in Patients with Claudin 6 Positive (CLDN6+) Platinum-Resistant Ovarian Cancer ...

Phase 2 study of cabozantinib (Cabo) and pembrolizumab (Pembro) in metastatic gastric/gastroesophageal adenocarcinoma (mGEA) resistant or refractory to immune checkpoint inhibitors (ICI). A phase ...

(MENAFN- GlobeNewsWire - Nasdaq) The Claudin18.2 targeted therapy market offers significant opportunities in treating advanced cancers such as gastric and pancreatic. With one approved therapy and ...

BASEL, Switzerland--(BUSINESS WIRE)--Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, ...

SHANGHAI and GAITHERSBURG, Md., March 3, 2022 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and ...

T-cell engagers (TCEs) are a new class of immuno-oncology therapies that have proven effective for the treatment of both solid tumors and hematological malignancies. Among validated targets in this ...

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) vs chemo in patients (pts) with advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma (GC/GEJC/EAC): ...

Bispecific T-cell-engaging antibodies have emerged as therapeutic options for the treatment of cancer, but limitations such as short half-life remain to be addressed. Researchers from Biontech SE ...